Verona Pharma raised US-$77.8m at NASDAQ British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing … more ➔
Epigenomics in €171m take-over Epigenomics and minority shareholder Cathay Fortune International Company have agreed for Cathay to take over the Berlin-based diagnostics company for €7.52 per share – a premium of almost 50%. more ➔
Euronext-listed Argenx plans €68.6m IPO...Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and … more ➔
EMA backs authorisation of biologicsFour orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market approval by the European Medicines Agency’s CHMP this month. more ➔
Uniqure withdraws €1m drug Glybera from...With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its … more ➔
GE partner Synpromics completes financing...Synthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round with existing investors. more ➔
Galapagos raises US$338mAutoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares (ADSs) in an follow-on offering led by Morgan Stanley at $90 per ADS. more ➔
Allergan and Novartis combine NASH candida...Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH candidates cenicriviroc (Allergan) and FXR agonist LJN452 (Novartis). more ➔
bestbion dx to market sphingotec’s p...sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest bio-ADM) and acute kidney function monitoring … more ➔
Galenica exercises over-allotment optionFollowing its CHF1.901bn IPO at SIX Swiss Exchange on 7 April, Galenica Santé has announced full excercise of the over-allotment option worth CHF248m. more ➔
